Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Expected to Announce Quarterly Sales of $460,000.00


Share on StockTwits

Analysts expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to report $460,000.00 in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Infinity Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $200,000.00 and the highest estimate coming in at $690,000.00. Infinity Pharmaceuticals posted sales of $430,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 7%. The firm is expected to report its next earnings results on Monday, May 10th.

According to Zacks, analysts expect that Infinity Pharmaceuticals will report full year sales of $2.11 million for the current fiscal year, with estimates ranging from $800,000.00 to $3.44 million. For the next year, analysts expect that the business will post sales of $3.42 million, with estimates ranging from $800,000.00 to $7.22 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Infinity Pharmaceuticals.

Infinity Pharmaceuticals (NASDAQ:INFI) last posted its quarterly earnings results on Monday, March 15th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.16). Infinity Pharmaceuticals had a negative return on equity of 1,358.77% and a negative net margin of 2,592.65%.

A number of research firms have issued reports on INFI. B. Riley lowered their price target on Infinity Pharmaceuticals from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, March 23rd. Wells Fargo & Company boosted their price target on Infinity Pharmaceuticals from $2.00 to $4.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 23rd. Oppenheimer upped their target price on Infinity Pharmaceuticals from $5.50 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, February 11th. Piper Sandler assumed coverage on Infinity Pharmaceuticals in a research report on Thursday, February 25th. They issued an “overweight” rating and a $7.00 target price for the company. Finally, Truist assumed coverage on Infinity Pharmaceuticals in a research report on Thursday, March 18th. They issued a “buy” rating and a $12.00 target price for the company. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Infinity Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $8.31.

In related news, major shareholder Bvf Partners L. P/Il sold 5,848,520 shares of the stock in a transaction dated Friday, January 22nd. The stock was sold at an average price of $4.14, for a total value of $24,212,872.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 13.77% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Private Wealth Advisors Inc. acquired a new stake in Infinity Pharmaceuticals during the fourth quarter valued at approximately $25,000. Morgan Stanley raised its stake in Infinity Pharmaceuticals by 268.9% during the third quarter. Morgan Stanley now owns 35,251 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 25,695 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Infinity Pharmaceuticals by 165,024.0% during the fourth quarter. JPMorgan Chase & Co. now owns 41,281 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 41,256 shares in the last quarter. Callan Capital LLC acquired a new stake in Infinity Pharmaceuticals during the fourth quarter valued at approximately $155,000. Finally, BlackRock Inc. raised its stake in Infinity Pharmaceuticals by 0.6% during the fourth quarter. BlackRock Inc. now owns 976,446 shares of the biotechnology company’s stock valued at $2,071,000 after buying an additional 5,748 shares in the last quarter. Hedge funds and other institutional investors own 46.66% of the company’s stock.

INFI stock traded up $0.17 during trading on Monday, reaching $3.51. 35,600 shares of the stock traded hands, compared to its average volume of 3,897,280. The business’s 50 day moving average price is $3.27 and its 200-day moving average price is $2.43. Infinity Pharmaceuticals has a 52-week low of $0.78 and a 52-week high of $5.98. The firm has a market capitalization of $311.13 million, a PE ratio of -4.70 and a beta of 2.40.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Read More: What is a Candlestick Chart?

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.